FDA approves Infilbray for neurological symptoms of Type 3 Gaucher disease
The FDA approved Infilbray (venglustat) for neurological symptoms of Type 3 Gaucher disease in patients weighing at least 15 kg, backed by a 43-patient Phase 3 trial (p=0.0137). The approval provides the first treatment crossing the blood-brain barrier for these symptoms.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and pediatric patients weighing at least 15 kg (approximately 33 pounds), supported by a 43-patient clinical study, the FDA said. In the Phase 3 LEAP2MONO trial, patients taking once-daily oral Infilbray showed statistically significant superiority over intravenous enzyme replacement therapy (imiglucerase) on a combined neurological primary outcome (p=0.0137), Sanofi said. The approval, granted to Genzyme Corporation, a Sanofi Company, brings patients and healthcare providers the first approved drug that crosses the blood-brain barrier for neurological symptoms of GD3, the agency said.
Why it matters
Treatment options for types 1 and 3 Gaucher disease have included medicine and enzyme replacement therapy, with no good treatment for the brain damage of types 2 and 3, NIH MedlinePlus notes. "We have been able to treat the systemic manifestations of Type 3 Gaucher disease, while the neurological manifestations remained beyond the reach of available therapies," Dr. Pramod Mistry, Director of the Yale Lysosomal Disease Center and Gaucher Disease Treatment Center, said in the Sanofi release. Sanofi ran LEAP2MONO (NCT05222906) to evaluate daily oral venglustat against intravenous Cerezyme infusions every two weeks for improvement or stabilization of neurological manifestations and maintenance of systemic disease stability in patients treated with enzyme replacement therapy for at least 3 years, the study record shows.
LEAP2MONO results and regulatory review
The FDA approved Infilbray on November 18, 2026, granting the drug Orphan Drug designation and Priority Review, the agency said. Infilbray also received rare pediatric disease designation and fast-track designation in the US, along with orphan designation for GD3 in the EU, US and Japan, Sanofi said.
Infilbray is a once-daily oral glucosylceramide synthase inhibitor (GCSi) that crosses the blood-brain barrier to reduce the buildup of harmful fatty substances called glucosphingolipids (also termed glycosphingolipids, or GSLs) in the body and brain, the FDA and Sanofi said.
In the randomized, double-blind, double-dummy LEAP2MONO trial, 43 patients aged 12 years and older were assigned 1:1 to once-daily oral Infilbray plus placebo infusion (n=21) or intravenous imiglucerase every two weeks plus placebo tablet (n=22) for 52 weeks, Sanofi and the ClinicalTrials.gov record state.
The primary outcome used a prespecified O'Brien ordinary least squares global test combining two Week 52 neurological assessments:
- Change from baseline to Week 52 in the modified Scale for the Assessment and Rating of Ataxia (4-item SARA score), assessing ataxia (loss of muscle control and coordination)
- Change from baseline to Week 52 in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total scale index score, assessing cognitive function
At Week 52, patients receiving Infilbray demonstrated improvement on that combined neurological measure compared with those taking imiglucerase, achieving statistically significant superiority (p=0.0137), the FDA and Sanofi said.
Participants and trial structure
LEAP2MONO enrolled adults aged 18 years and older and pediatric patients aged 12 to under 18 years weighing at least 30 kg who had a clinical diagnosis of GD3 confirmed by acid beta-glucosidase deficiency, a modified SARA score of 1 or above, and horizontal gaze palsy, the ClinicalTrials.gov record shows. Participants had received enzyme replacement therapy for at least 3 years, on a stable dose for at least 6 months, and were clinically stable for at least 1 year within systemic therapeutic goals, the study record states.
The multinational trial includes a 45-day screening period, the 52-week double-blind primary analysis period, an open-label extended treatment period of at least 52 weeks in which all participants receive oral venglustat, and a follow-up phone call 30-37 days after treatment ends, the registry record states. Other measures through Week 52 track spleen volume, liver volume, hemoglobin level, platelet count, and cerebrospinal fluid and plasma GL-1 and lyso-GL-1 levels, the record lists.
Safety and Warnings and Precautions
In the 52-week primary analysis period of LEAP2MONO, reported adverse reactions among patients receiving Infilbray (n=21) versus imiglucerase (n=22) were, Sanofi stated:
- diarrhea: 14% versus 0%
- splenomegaly: 14% versus 0%
- nausea: 14% versus 5%
- depression: 10% versus 0%
- gastroenteritis: 10% versus 0%
- vomiting: 10% versus 5%
The most frequently reported side effects of Infilbray include gastrointestinal symptoms and adverse effects on mood, and serious psychiatric risks including suicidal ideation and behavior have been reported, the FDA said. Animal studies identified potential clouding of vision in younger patients and adverse effects on fetal development when the drug is taken during pregnancy, the agency said. Infilbray carries Warnings and Precautions for Suicidal Ideation and Behavior, Lens Opacification in Pediatric Patients, and fetal toxicity, Sanofi and the FDA noted.
What remains uncertain
The open-label phase of LEAP2MONO is ongoing, and results from that phase are not yet available, Sanofi said. Infilbray remains under regulatory review for GD3 in the EU, Japan and other jurisdictions worldwide, with additional global submissions planned in 2026 and 2027, Sanofi said. Summary trial results are not yet posted in the ClinicalTrials.gov record, which lists LEAP2MONO as active, not recruiting.
Sources
- FDA: FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease (November 18, 2026)
- Sanofi: Sanofi's Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease (November 18, 2026)
- ClinicalTrials.gov: Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 (NCT05222906)
- NIH MedlinePlus: Gaucher Disease (September 27, 2026)